Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioVersys AG ( (CH:BIOV) ) has shared an update.
BioVersys will showcase new clinical and preclinical data on its BV100 and BV500 programs at ESCMID Global 2026, underlining its ambition to become a key player in the fight against antimicrobial resistance. At the congress in Munich, the company and academic collaborators from the U.K., Greece and Switzerland will present posters demonstrating BV100’s activity against carbapenem‑resistant Acinetobacter baumannii and BV500’s broad‑spectrum efficacy against non‑tuberculous mycobacteria.
Data from in vitro and in vitro pharmacokinetic models suggest BV100 retains activity against drug‑resistant A. baumannii, enhances bacterial killing when combined with polymyxin B or cefiderocol, and can help delay or suppress resistance emergence compared with standard regimens. BV500 lead compounds BV500‑1 and BV500‑2, developed with public‑private partnerships and under a collaboration with Shionogi, show potent in vitro and in vivo activity against M. abscessus and other NTM, reinforcing BioVersys’ positioning in AMR innovation as its CEO also contributes to policy discussions on funding and research priorities at the meeting.
The most recent analyst rating on (CH:BIOV) stock is a Buy with a CHF40.00 price target. To see the full list of analyst forecasts on BioVersys AG stock, see the CH:BIOV Stock Forecast page.
More about BioVersys AG
BioVersys AG (SIX: BIOV) is a Basel‑based, multi‑asset, clinical‑stage biopharmaceutical company developing novel antibacterial therapies for serious, life‑threatening infections caused by multidrug‑resistant bacteria. Its pipeline includes BV100 for carbapenem‑resistant Acinetobacter baumannii‑calcoaceticus complex infections and BV500 candidates for non‑tuberculous mycobacterial diseases, targeting major unmet medical needs in hospital and chronic lung infections.
Average Trading Volume: 3,577
Technical Sentiment Signal: Buy
Current Market Cap: CHF155M
Find detailed analytics on BIOV stock on TipRanks’ Stock Analysis page.